OC 13 - ITP - Current and potential second-line therapy

Moderator(s)

• 

  Robert Flaumenhaft, MD, PhD

  Professor
  BIDMC/Harvard Medical School
  Boston, Massachusetts, United States
• 

  Nuanrat Cheerasiri, MD

  Lecturer
  Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital
  bangkok, Krung Thep, Thailand

Presentations:

• 09:30 – 09:45 ICT

  Long-Term Impact of Splenectomy on Immune Status in Patients with ITP
  

  Presenting Author: Huiyuan Li, MD – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China

  Co-Author: Yunfei Chen – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases

  Co-Author: Lei Zhang – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China
• 09:45 – 10:00 ICT

  Proteomics Landscape and Machine Learning Prediction of Long-term Response to Splenectomy in Primary Immune Thrombocytopenia
  

  Presenting Author: Jia Chen, MD – Chinese academy of medical sciences

  Co-Author: Ting Sun – Chinese academy of medical science

  Co-Author: Yunfei Chen – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases

  Co-Author: Renchi Yang, MD – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

  Co-Author: Lei Zhang – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China
• 10:00 – 10:15 ICT

  Pooled Analysis of the Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Previously Treated Immune Thrombocytopenia: Phase 2 Study
  

  Presenting Author: David J. Kuter, MD, DPhil – Hematology Division, Massachusetts General Hospital, Harvard Medical School

  Co-Author: Robert Bird – Princess Alexandra Hospital

  Co-Author: A. J. Gerard Jansen – Erasmus MC

  Co-Author: Umer Khan – Sanofi, Cambridge, MA, USA

  Co-Author: Ahmed Daak – Sanofi

  Co-Author: Nichola Cooper – Hammersmith Hospital
• 10:15 – 10:30 ICT

  Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China
  

  Presenting Author: Zhifa Wang, PhD – Department II of Hematology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, 100045, China

  Co-Author: Nan Wang, Master student – Beijing Children’s Hospital, Capital Medical University,

  Co-Author: Jingyao Ma – Beijing Children’s Hospital, Capital Medical University,

  Co-Author: Xiaoling Cheng – Beijing Children’s Hospital, Capital Medical University,

  Co-Author: Runhui Wu, PhD, MD – Department of Hematology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, 100045, China
• 10:30 – 10:45 ICT

  DPP4 inhibitor restores immune tolerance and thrombopoiesis in Immune thrombocytopenia
  

  Co-Author: Fengjiao Han – Department of Hematology, Qilu Hospital

  Presenting Author: Miao Xu, PhD,MD – Department of Hematology, Qilu Hospital